Extra-pancreatic effects of incretin-based therapies (Q38194069)

30 August 2017

1 reference

title

Extra-pancreatic effects of incretin-based therapies (English)

1 reference

30 August 2017

Baptist Gallwitz

1

1 reference

30 August 2017

7 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

47

1 reference

30 August 2017

2

1 reference

30 August 2017

360-371

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-014-0223-0

30 August 2017

0 references

cites work

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

ABC of arterial and venous disease: vascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Anorexigenic effects of GLP-1 and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Peripheral glucagon-like peptide-1 (GLP-1) and satiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Lixisenatide: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

DPP-4 inhibition and neuroprotection: do mechanisms matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Diabetes mellitus, fasting glucose, and risk of cause-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Direct cardiovascular effects of glucagon like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Effects of incretin-based therapy in patients with heart failure and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide-associated ischemic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Incretin therapy and islet pathology: a time for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-014-0223-0

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

21 January 2018

1 reference

12 December 2020

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

1 reference

12 December 2020

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

12 December 2020

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

1 reference

12 December 2020

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

1 reference

12 December 2020

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

12 December 2020

Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions

1 reference

12 December 2020

Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis

1 reference

12 December 2020

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Entry of exendin-4 into brain is rapid but may be limited at high doses

1 reference

12 December 2020

A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects

1 reference

12 December 2020

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes

1 reference

12 December 2020

Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

1 reference

12 December 2020

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

1 reference

12 December 2020

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

12 December 2020

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

1 reference

12 December 2020

10.1007/S12020-014-0223-0

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24604239